

HR 4209

Patients' Access to Treatments Act of 2012

Congress: 112 (2011–2013, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 19, 2012

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 19, 2012)

Official Text: <https://www.congress.gov/bill/112th-congress/house-bill/4209>

Sponsor

Name: Rep. McKinley, David B. [R-WV-1]

Party: Republican • **State:** WV • **Chamber:** House

Cosponsors (43 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Capps, Lois [D-CA-23]	D · CA		Mar 19, 2012
Rep. Cuellar, Henry [D-TX-28]	D · TX		Mar 19, 2012
Rep. Frank, Barney [D-MA-4]	D · MA		Mar 19, 2012
Rep. Young, C. W. Bill [R-FL-10]	R · FL		Mar 19, 2012
Rep. Harper, Gregg [R-MS-3]	R · MS		Mar 28, 2012
Rep. Conyers, John, Jr. [D-MI-14]	D · MI		Apr 16, 2012
Rep. McGovern, James P. [D-MA-3]	D · MA		Apr 16, 2012
Rep. Bartlett, Roscoe G. [R-MD-6]	R · MD		Apr 19, 2012
Rep. Deutch, Theodore E. [D-FL-19]	D · FL		Apr 19, 2012
Rep. Farr, Sam [D-CA-17]	D · CA		Apr 19, 2012
Rep. Rothman, Steven R. [D-NJ-9]	D · NJ		Apr 19, 2012
Rep. Bonner, Jo [R-AL-1]	R · AL		Apr 24, 2012
Rep. Crenshaw, Ander [R-FL-4]	R · FL		Apr 24, 2012
Rep. Jackson, Jesse L., Jr. [D-IL-2]	D · IL		Apr 24, 2012
Rep. Bachus, Spencer [R-AL-6]	R · AL		May 9, 2012
Rep. Langevin, James R. [D-RI-2]	D · RI		May 9, 2012
Rep. Pingree, Chellie [D-ME-1]	D · ME		May 9, 2012
Rep. Roybal-Allard, Lucille [D-CA-34]	D · CA		May 9, 2012
Rep. Tonko, Paul [D-NY-21]	D · NY		May 9, 2012
Rep. Young, Don [R-AK-At Large]	R · AK		May 9, 2012
Rep. Cicilline, David N. [D-RI-1]	D · RI		Jun 5, 2012
Rep. Moran, James P. [D-VA-8]	D · VA		Jun 7, 2012
Rep. Davis, Susan A. [D-CA-53]	D · CA		Jul 19, 2012
Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]	D · GA		Jul 19, 2012
Rep. Boswell, Leonard L. [D-IA-3]	D · IA		Sep 12, 2012
Rep. Courtney, Joe [D-CT-2]	D · CT		Sep 12, 2012
Rep. Gerlach, Jim [R-PA-6]	R · PA		Sep 12, 2012
Rep. Holt, Rush [D-NJ-12]	D · NJ		Sep 12, 2012
Rep. Michaud, Michael H. [D-ME-2]	D · ME		Sep 12, 2012
Rep. Pastor, Ed [D-AZ-4]	D · AZ		Sep 12, 2012
Rep. Rangel, Charles B. [D-NY-15]	D · NY		Sep 12, 2012
Rep. Runyan, Jon [R-NJ-3]	R · NJ		Sep 12, 2012
Rep. Wolf, Frank R. [R-VA-10]	R · VA		Sep 12, 2012
Rep. Woolsey, Lynn C. [D-CA-6]	D · CA		Sep 12, 2012
Rep. Capito, Shelley Moore [R-WV-2]	R · WV		Sep 20, 2012
Rep. Davis, Danny K. [D-IL-7]	D · IL		Sep 20, 2012
Rep. Markey, Edward J. [D-MA-7]	D · MA		Sep 20, 2012
Rep. Towns, Edolphus [D-NY-10]	D · NY		Sep 20, 2012
Rep. Bishop, Timothy H. [D-NY-1]	D · NY		Sep 21, 2012
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Sep 21, 2012
Rep. McDermott, Jim [D-WA-7]	D · WA		Nov 30, 2012

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Dec 11, 2012
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Dec 12, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 19, 2012

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 19, 2012)

Patients' Access to Treatments Act of 2012 - Amends the Public Health Service Act to prohibit a health plan offering group or individual health insurance that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure from imposing co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount of such requirements applicable to prescription drugs in a non-preferred brand drug tier.

Provides that if a formulary used by such a health plan contains more than one non-preferred brand drug tier, such prohibition shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.

Defines: (1) "non-preferred brand drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs or preferred brand drugs in the plan's formulary, that are prescription drugs, and that are not included within a specialty drug tier; and (2) "specialty drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan's formulary and that are prescription drugs.

Actions Timeline

- **Mar 19, 2012:** Introduced in House
- **Mar 19, 2012:** Referred to the House Committee on Energy and Commerce.